2019


- Parulekar WR, Berrang T, Kong I, Rakovitch E, Theberge V, Gelmon KA, Chia SKL,


2018


• Gray R, Early Breast Cancer Trialists Collaborative Group, Early. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-


2017


- Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon KA, Whelan TJ,


Donadey F, Franceschi E, Chinot OL, Winch C, Ding K, Mason WP. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J Clin Oncol 34[suppl; abstr LBA2]. 2016.


- Tinker A, Hirte H, Provencher D, Butler M, Ritter H, Tu D, Paralejas P, Grenier S, Hahn


2015

• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[ suppl; abstr e17710].


- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[ suppl; abstr 6]. 2015.


TJ, Montenegro A, O'Sullivan B, Parulekar WR. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMAb) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol 33[suppl; abstr 6000].


2014


- Bonomi M, Xu H, Laurie SA, Eisenhauer EA, Tu D, Pater JL, Seymour L, Bradbury PA. The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-


chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. J Clin Oncol 32:5s[suppl; abstr 4009]. 2014.


2013


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[Suppl; abstr 6557], 2013.
- Pavlakis N, Goldstein D, Sjoquist KM, Martin A, Tsobanis E, Yip S, Shannon J, Burge


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[ suppl; abstr 4061], 2013.


2012


• Eigl BJ, North S, Winquist E, Powers J, Good J, Sharma M, Squire J, Cox M,


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


2011


- Chapman JW, O’Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG,


Hilton JF, Seymour L, Le Maître A, Tu D, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


2011.


- Stiff PJ, Unger M, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP,


**2010**

- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.

- Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Shustik


2009

- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.
- Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.
- Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-


Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Tan X, Takahara G, Tu D. Two-stage design for phase II cancer clinical trials with responses and early progression as coprimary endpoints. Statistical Society of Canada,
2008.


Part I, 437s, 2008.


2007


- Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O'Reilly SE, Graham B, Shepherd LE. How compliant are patients with


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


White D, Kovacs M, Belch A, Stewart K, Chen C, Rubin S, Macdonald D, Harnett E,

2006


• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


• Pater JL, Tu D, Ingle JN, Shepherd LE, Goss PE. An evaluation of the early termination of MA.17 extended adjuvant therapy trial. Breast Cancer Treatment and Research 100[Suppl 1], S107, 2006.


• Pollak M, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KL. Insulin resistance, estimated by serum C-peptide level, is associated with


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

• Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


• Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.

• Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.

• Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN,


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

- Wong R, Paul N, Ding K, Brundage M, Fyles A, Pater J. Optimizing prophylaxis of
radiation induced emesis: a phase III double blind randomized study comparing 
ondansetron plus dexamethasone vs ondansetron alone. Support Care Cancer 13[6], 
423, 2005.

2004

- Assouline S, Eisenhauer E. RECIST (Response Evaluation Criteria in Solid Tumors) 
E. Phase II trial of bortezomib in mantle cell lymphoma. Blood (ASH Annual Meeting 
- Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner 
J, Fink K, Souhami L, Curran W. An intergroup randomized controlled clinical trial of 
chemotherapy plus radiation versus radiation alone for pure and mixed anaplastic 
2004.
- Chen C, White D, Kouroukis T, Stewart KA, Howson-Jan K, Larratt L, Powers J, 
Eisenhauer E. Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of 
patients with previously untreated or treated Waldenstrom's Macroglobulinemia. Blood 
- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Hurtado-Coll A, Goldenberg L, 
Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 
2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer 
- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave 
ME. A phase I pharmacokinetic and pharmacodynamic study of OXG-011, a 
2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer 
- Chi K.N., Eisenhauer E, Fazli L, Jones T, Powers J, Ayers D, Goldenberg L, Gleave ME. 
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'methoxyethyl 
phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical 
- Ciuleanu TE, Shepherd F, Pereira J, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Ding 
K, Ptaszynski M, Seymour L. NCIC Clinical Trials Group trial BR.21. A placebo-
controlled trial of erlotinib in patients with advanced non-small cell lung cancer. NCIC 
- Colacchio TA, Niedzwiecki D, Compton CC, Warren RS, Benson AIB, Goldberg RM, 
Kerr D, Fields A, Hollis D, Mayer RJ. Phase III study of adjuvant immunotherapy with 
MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 
- Crump M, Leber B, Kassis J, Hedley D, Minden M, Buckstein R, McIntosh L, Eisenhauer 
E, Seymour L. A randomized phase I clinical and biologic study of two schedules of BAY 
43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC 
- Delaunoit TP, Kroof J, Sargent DJ, Green E, Alberts SR, Fuchs C, Ramanathan R,

Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E,


alone in stage III colon cancer (intergroup trial CALGB C89803).


2003


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


2002


confirms a survival advantage of the paclitaxel-cisplatin regimen over the

  Turner R, Shepherd L, Iglesias J. Gemcitabine, dexamethasone, cisplatin (GDP)

- Crump M, Baetz T, Belch A, Couban S, Meyer R, Imrie K, Howson-Jan K, Myers R,
  Adams G, Turner R, Paul N, Shepherd L, Iglesias J. Gemcitabine, dexamethasone,

  D, Petrenciu O, McIntosh L, Seymour L. A randomized phase I clinical and biologic
  study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with
  myelodysplastic syndrome or acute myeloid leukemia: a NCI Canada Clinical Trials

- Ernst S, Tannock I, Venner P, Winquist E, Reyno L, Walker H, Ding K, Elliott C,
  Parulekar W. Randomized placebo controlled trial of mitoxantrone/prednisone and
clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory
  21(part 1), 177a, 2002.

- Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK,
  Findlay BP. N9741: oxaliplatin or CP-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in
  advanced colorectal cancer. Initial toxicity and response data from a GI intergroup study.

  I, Seymour L. Initial results of part 2 of a phase II pharmacokinetics, pharmacodynamic
  and biological activity study of ZD1839 (Iressa): NCIC CTG IND.122.

  man dose escalation and pharmacokinetic study of the novel nucleoside analog

- Gridelli C, Shepherd F, Perrone F, Illiano A, Piantedosi F, Robbiati S, Manzione L,
  Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Findlay B, Hirsh V, Seymour L,
  Bejak A, Gallo C. GEMVIN III: A phaseII study of gemcitabine plus vinorelbine
  compared to cisplatin plus vinorelbine or gemcitabine chemotherapy for stage IIIB or
  21(part 1), 16a, 2002.

- Hamilton M, Wolf J, Demetri G, Seiden M, de Vries E, Eisenhauer E, Gelmon K,
  Hammond A, Rowinsky E, Hirte H, Rothenberg M, Verweij J, Sparreboom A, Versluis J,
  Culbertson J, Roberts L, Ptaszynski M, Santabarbara P. Phase I pharmacokinetics of
  21(part 1), 90a, 2002.

- Hayter C, Lukka H. Process and outcome of real-time radiotherapy review in a national
  study of prostate cancer radiotherapy. Int.J.Rad.Oncol.Biol.Phys. 54[2(suppl 1)], 276,
  2002.

- Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Onetto N.


2001


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 19, 198a, 2000.


Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Elias I, Matthews S, Seymour L. NCIC CTG IND 113: Two phase I dose escalation pharmacokinetic studies of BAY 12-9566 in


\[1998\]


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial.


1997


- Bertelsen K, Kaern J, Simonsen E, Piccart M, Hoctin Boes G, Timmers P, Roy JA,


Roche K, Paul N, Walker H, Zee B, Smuck B, Hiatt M, Brittain M. Measuring workload of


**1996**

on Cancer Nursing, 1996.


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.
- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


1994

- Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1993


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


1992


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


1991


**Abstracts**
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


**1990**

- Rusthoven J, Levin L, Eisenhauer E, Carmichael J. A phase I study of GM-CSF,


1989


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988

1987


1986

- Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I


- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981
